215804-67-4
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | HY-10847B | SB-277011 hydrochloride | 215804-67-4 | 5mg | 1000元 |
2024/11/08 | HY-10847B | SB-277011 hydrochloride | 215804-67-4 | 10mM * 1mLin DMSO | 1050元 |
2024/11/08 | HY-10847B | SB-277011 hydrochloride | 215804-67-4 | 10mg | 1600元 |
常見(jiàn)問(wèn)題列表
D 3 Receptor 10.7-11.2 nM (Ki) |
D 2 Receptor
|
5-HT 1D Receptor
|
5-HT 1B Receptor
|
SB-277011 hydrochloride has an excellent pharmacokinetic profile, exhibits oral bioavailability 43%, half-life:2.0 h, plasma clearance 19 mL/min/kg) and to be highly brain-penetrant (brain:blood ratio of 3.6:1), with a clean P450 profile in the rat.SB-277011 hydrochloride (SB 277011; 3 mg/kg, p.o.) completely reverses the effects of quinelorane in the nucleus accumbens, but does not reverse the effects of quinelorane in the striatum at 93 mg/kg in rats.SB-277011 (intraperitoneal injection; 12.5-25 mg/kg) significantly and dose-dependently reduces intravenous cocaine self-administration under both low fixed-ratio and progressive-ratio reinforcement conditions in rats. When it increases to 50 mg/kg, SB-277011 can significantly inhibit basal and cocaine-enhanced locomotion in rats.